FXR1 and cancer: Five doxycycline (Dox)-inducible FXR1 shRNAs were tested and most of them resulted in robust downregulation of FXR1 protein level and exhibited anti-proliferative activity in the TP53/FXR2 co-deleted cancer cell line KATOIII, but not in the copy-number-normal cell line MKN45 (Figure 1—figure supplement 3A).